{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:23:10Z","timestamp":1794277390565,"version":"4.9.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jneuroim.2018.07.009","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:14:26Z","timestamp":1532477666000},"page":"62-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"special_numbering":"C","title":["Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction"],"prefix":"10.1016","volume":"323","author":[{"given":"Divyanshu","family":"Dubey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Kothapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda A.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elson","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley F.","family":"Boeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Mendelt","family":"Tillema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-6030","authenticated-orcid":false,"given":"Reza","family":"Sadjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jneuroim.2018.07.009_bb0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol."},{"issue":"12","key":"10.1016\/j.jneuroim.2018.07.009_bb0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2018.07.009_bb0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jneuroim.2018.07.009_bb0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.seizure.2015.04.007","article-title":"Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy","volume":"29","author":"Dubey","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.jneuroim.2018.07.009_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jneuroim.2015.08.014","article-title":"The spectrum of autoimmune encephalopathies","volume":"287","author":"Dubey","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2018.07.009_bb0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1756285616656295","article-title":"Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis","volume":"9","author":"Dubey","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.07.009_bb0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","article-title":"Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2018.07.009_bb0040","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/epi.13797","article-title":"Predictive models in the diagnosis and treatment of autoimmune epilepsy","volume":"58","author":"Dubey","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.jneuroim.2018.07.009_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jneuroim.2018.04.016","article-title":"Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year","volume":"321","author":"Dubey","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2018.07.009_bb0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune Encephalitis Epidemiology and a comparison to Infectious Encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2018.07.009_bb0055","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","article-title":"Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis","volume":"73","author":"Fang","year":"2016","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2018.07.009_bb0060","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4065\/mcp.2010.0326","article-title":"Autoimmune dementia: clinical course and predictors of immunotherapy response","volume":"85","author":"Flanagan","year":"2010","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.jneuroim.2018.07.009_bb0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2018.07.009_bb0070","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/cid\/cir1038","article-title":"The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project","volume":"54","author":"Gable","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jneuroim.2018.07.009_bb0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.jneuroim.2018.07.009_bb0080","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1473-3099(10)70222-X","article-title":"Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study","volume":"10","author":"Granerod","year":"2010","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.jneuroim.2018.07.009_bb0085","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jneuroim.2018.07.009_bb0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2018.07.009_bb0095","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"14","key":"10.1016\/j.jneuroim.2018.07.009_bb0100","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/1078-0432.CCR-14-0652","article-title":"Neural autoantibody clusters aid diagnosis of cancer","volume":"20","author":"Horta","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jneuroim.2018.07.009_bb0105","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ana.22307","article-title":"Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis","volume":"69","author":"Irani","year":"2011","journal-title":"Ann. Neurol."},{"issue":"Pt 10","key":"10.1016\/j.jneuroim.2018.07.009_bb0110","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/brain\/awt212","article-title":"Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype","volume":"136","author":"Irani","year":"2013","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jneuroim.2018.07.009_bb0115","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000386","article-title":"Frequencies of neuronal autoantibodies in healthy controls: Estimation of disease specificity","volume":"4","author":"Lang","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.jneuroim.2018.07.009_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12883-017-0974-3","article-title":"Application of the 2016 diagnostic approach for autoimmune encephalitis from Lancet Neurology to Chinese patients","volume":"17","author":"Li","year":"2017","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.07.009_bb0125","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0034-1390394","article-title":"Neuronal surface antibody-mediated autoimmune encephalitis","volume":"34","author":"Linnoila","year":"2014","journal-title":"Semin. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2018.07.009_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000404","article-title":"Improving the antibody-based evaluation of autoimmune encephalitis","volume":"4","author":"McCracken","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2 Dementia","key":"10.1016\/j.jneuroim.2018.07.009_bb0135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1212\/CON.0000000000000299","article-title":"Autoimmune encephalopathies and dementias","volume":"22","author":"McKeon","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.1016\/j.jneuroim.2018.07.009_bb0140","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00401-011-0876-1","article-title":"Paraneoplastic encephalomyelopathies: pathology and mechanisms","volume":"122","author":"McKeon","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.jneuroim.2018.07.009_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/mus.25565","article-title":"GAD65 neurological autoimmunity","volume":"56","author":"McKeon","year":"2017","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jneuroim.2018.07.009_bb0150","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archneurol.2009.78","article-title":"Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments","volume":"66","author":"McKeon","year":"2009","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.07.009_bb0155","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/mus.23774","article-title":"Striational antibodies in a paraneoplastic context","volume":"47","author":"McKeon","year":"2013","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jneuroim.2018.07.009_bb0160","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2018.07.009_bb0165","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archneurol.2011.2985","article-title":"Autoimmune epilepsy: clinical characteristics and response to immunotherapy","volume":"69","author":"Quek","year":"2012","journal-title":"Arch. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2018.07.009_bb0170","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1161\/STROKEAHA.109.557256","article-title":"Reliability of the modified Rankin Scale: a systematic review","volume":"40","author":"Quinn","year":"2009","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.jneuroim.2018.07.009_bb0175","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.jneuroim.2018.07.009_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2018.07.009_bb0185","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/CON.0000000000000487","article-title":"Autoimmune neurology of the central nervous system","volume":"23","author":"Tobin","year":"2017","journal-title":"Continuum (Minneap Minn)"},{"issue":"18","key":"10.1016\/j.jneuroim.2018.07.009_bb0190","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1212\/WNL.0000000000000383","article-title":"Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy","volume":"82","author":"Toledano","year":"2014","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.jneuroim.2018.07.009_bb0195","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0000000000002637","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"86","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jneuroim.2018.07.009_bb0200","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4065\/73.12.1161","article-title":"Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus","volume":"73","author":"Walikonis","year":"1998","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.jneuroim.2018.07.009_bb0205","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/mus.25027","article-title":"P\/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments","volume":"54","author":"Zalewski","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818302832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818302832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:32:18Z","timestamp":1759048338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572818302832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":41,"alternative-id":["S0165572818302832"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.07.009","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}